Kaplan-Meier graphs for breast cancer incidence in the tamoxifen

Incidence and Survival by Human Epidermal Growth Factor Receptor 2 Status in Young Women With Stage I-III Breast Cancer: SEER, 2010-2016 - Clinical Breast Cancer

Ivana SESTAK, Associate Professor in Medical Statistics

Cumulative incidence rates for all breast cancers and invasive estrogen

CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance

Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study - Modern Pathology

A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy

Figure 3 from Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

Full article: Excavating the pathogenic gene of breast cancer based on high throughput data of tumor and somatic reprogramming

Cancers, Free Full-Text

The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials - ScienceDirect